ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Ultrasound Therapy for Fibromyalgia and Lyme Disease

Curcumin: The All In One Solution, Part 2

What Are the Benefits of Vitamin K2?

Vitamin D deficiency + high fat diet = metabolic syndrome

Why You Should Take Your Apple Cider Vinegar at Night

Use Burdock Oil to Promote Healthy Hair Growth

Meet Your Weight Loss Goals

AMA journal associates iron deficiency with hearing loss

People with forms of early-onset Parkinson's disease may benefit from boosting niacin in diet, resea...

Lutein linked to preservation of crystallized intelligence

 
Print Page
Email Article

Final Results of Milnacipran Phase II Study in Fibromyalgia Syndrome

  [ 1083 votes ]   [ Discuss This Article ]
www.ProHealth.com • February 24, 2003


SAN DIEGO, CA – February 10, 2003 – Cypress Bioscience, Inc. (NASDAQ:CYPB) announced topline final results of a Phase II clinical trial evaluating milnacipran as a treatment for fibromyalgia syndrome (FMS). Milnacipran was shown to provide statistically significant improvement of pain, the hallmark symptom of FMS. This trial is the first to evaluate milnacipran as a potential treatment for FMS.

FMS is a chronic pain syndrome that is estimated to affect 2-4% of the general population. The symptoms of FMS can be debilitating, and are characterized by chronic and widespread pain throughout the body, often accompanied by severe fatigue and poor sleep. Treatment options are limited as there are no drugs specifically approved by the U.S. Food and Drug Administration for the treatment of FMS.

There were a total of 125 patients enrolled in the double blind, placebo-controlled, flexible dose escalation mono-therapy trial. Patients were randomized to receive placebo or milnacipran (either once or twice per day) for four weeks of dose escalation, followed by eight weeks of constant dose. The study evaluated the efficacy and safety of milnacipran for the treatment of pain and associated symptoms such as fatigue, depressed mood and sleep.

Patients were asked to characterize their pain, fatigue, sleep quality and related symptoms several times each day on an electronic diary. The Company had reported results from a preliminary analysis of 95 patients from the trial in December 2002. Today’s announcement represents the final results, which include the entire 125 patients.

Milnacipran-treated patients randomized to the twice a day dosing group (BID) showed statistically significant improvements in pain compared to those who received placebo. Seventy percent of all milnacipran-treated patients reported overall improvement, compared to 36 percent in the placebo group (p=0.006). Further, 37 percent of milnacipran BID-treated patients reported at least a 50 percent reduction in pain intensity, compared to 14 percent of patients who received placebo, a difference that was statistically significant (p=0.0395, intent to treat analysis).

In addition, milnacipran-treated patients showed improvements in fatigue and depressed mood on multiple outcome measures.

"FMS is currently an incredibly challenging condition to manage clinically. If further studies confirm these data and this level of improvement in these patients, drugs like milnacipran could dramatically change the way we treat FMS," said Dr. Daniel Clauw, Professor of Medicine, Division of Rheumatology; Director, Center for Advancement of Clinical Research; and Director, Chronic Pain and Fatigue Research Center, The University of Michigan and Chairman of Cypress’ Rheumatology Advisory Board.

“These final results, similar to the preliminary results announced in December, suggest that milnacipran, a novel dual-acting reuptake inhibitor that acts on two key neurotransmitters, norepinephrine and serotonin, which are involved with the central modulation and processing of chronic pain, may have the potential to relieve not only pain but several of the other symptoms associated with FMS, and perhaps other related Functional Somatic Syndromes,” noted Jay D. Kranzler, MD, PhD, Chairman of the Board and Chief Executive Officer of Cypress Bioscience Inc.

Eighty-four percent of all milnacipran patients escalated to the highest dose with no tolerability issues. The most common dose-related side effect reported by patients was nausea, particularly early in the study. Most adverse events were mild to moderate in intensity, and transient in duration.
Further details of the data from the trial will be presented at the American Pain Society meeting in March 2003.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Vitamin D3 Extreme™ FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask
Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
The Brain Boosting and Fatigue Fighting B-12 The Brain Boosting and Fatigue Fighting B-12

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map